KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes...<< Prices as on Jun 20, 2024 - 3:59PM >>  ABB India 8542.9  [ 0.02% ]  ACC 2626.9  [ 0.26% ]  Ambuja Cements 659.15  [ -1.12% ]  Asian Paints Ltd. 2918  [ 0.88% ]  Axis Bank Ltd. 1237.9  [ 0.95% ]  Bajaj Auto 9622.1  [ -0.68% ]  Bank of Baroda 285.2  [ 0.48% ]  Bharti Airtel 1381.15  [ -0.86% ]  Bharat Heavy Ele 293.4  [ -1.21% ]  Bharat Petroleum 626.3  [ 1.66% ]  Britannia Ind. 5384.8  [ 0.46% ]  Cipla 1547.95  [ -0.73% ]  Coal India 483.15  [ 1.04% ]  Colgate Palm. 2859.6  [ -1.20% ]  Dabur India 600.7  [ 0.38% ]  DLF Ltd. 874.4  [ 1.70% ]  Dr. Reddy's Labs 5973  [ 0.31% ]  GAIL (India) 218.55  [ 1.02% ]  Grasim Inds. 2500  [ 2.14% ]  HCL Technologies 1446  [ 0.07% ]  HDFC 2729.95  [ -0.62% ]  HDFC Bank 1669  [ 0.66% ]  Hero MotoCorp 5513.2  [ -2.32% ]  Hindustan Unilever L 2478.1  [ 0.85% ]  Hindalco Indus. 676.75  [ 2.16% ]  ICICI Bank 1156.8  [ 1.05% ]  IDFC L 123.75  [ 2.19% ]  Indian Hotels Co 638.3  [ 3.46% ]  IndusInd Bank 1529  [ -0.03% ]  Infosys L 1515.3  [ 0.26% ]  ITC Ltd. 423.35  [ -0.08% ]  Jindal St & Pwr 1056.65  [ 0.93% ]  Kotak Mahindra Bank 1765.05  [ 0.96% ]  L&T 3597.1  [ 0.19% ]  Lupin Ltd. 1555.1  [ -1.12% ]  Mahi. & Mahi 2870.7  [ -2.10% ]  Maruti Suzuki India 12143.9  [ -0.75% ]  MTNL 41.71  [ -1.00% ]  Nestle India 2538  [ 0.51% ]  NIIT Ltd. 104.6  [ 2.25% ]  NMDC Ltd. 273.2  [ 4.24% ]  NTPC 357.9  [ -1.26% ]  ONGC 271.85  [ 0.11% ]  Punj. NationlBak 128.5  [ 0.19% ]  Power Grid Corpo 324.6  [ -0.90% ]  Reliance Inds. 2946.4  [ 1.00% ]  SBI 843.8  [ -1.03% ]  Vedanta 470.25  [ 4.86% ]  Shipping Corpn. 273.15  [ -0.51% ]  Sun Pharma. 1470.45  [ -2.24% ]  Tata Chemicals 1153.2  [ 4.23% ]  Tata Consumer Produc 1105.65  [ -0.04% ]  Tata Motors 978.1  [ 0.07% ]  Tata Steel 182.35  [ 1.28% ]  Tata Power Co. 444.2  [ 0.43% ]  Tata Consultancy 3786.6  [ -0.38% ]  Tech Mahindra 1392.1  [ 0.79% ]  UltraTech Cement 10951.5  [ -0.36% ]  United Spirits 1269  [ -0.23% ]  Wipro 490.5  [ -1.03% ]  Zee Entertainment En 155.55  [ 0.78% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....


  • Loading....


20 June 2024 | 04:06

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE059A01026 BSE Code / NSE Code 500087 / CIPLA Book Value (Rs.) 289.87 Face Value 2.00
Bookclosure 02/08/2024 52Week High 1582 EPS 51.04 P/E 30.27
Market Cap. 124749.42 Cr. 52Week Low 986 P/BV / Div Yield (%) 5.33 / 0.84 Market Lot 1.00
Security Type Other

History of Company

The company history sections lists out major chronological events that happened to the company.

- The Company was Incorporated at Mumbai.


- The Company acquired a plot of land from MIDC at Patalganga in Kulaba district of Maharashtra State about 55 kms. from Mumbai.

- 18,773 Bonus equity shares issued in proportion 1:1.


- The name of the Company was changed from The Chemical Industrial & Pharmaceutical Laboratories Ltd., to the present one with effect from 20th July.


- 37,546 Bonus equity shares issued in proportion 1:1 in January 1986.


- During August, the Company obtained the consent of the Controller of Capital Issues to issue 3,00,000-15% secured non-convertible redeemable debentures of Rs 100 each aggregating to Rs 300 lakhs by private placement. The entire issue was subscribed by public financial institutions. They are redeemable at a premium of 5% during 1993-94.


- The Company launched several new products viz., Asthalin and Beclate Rotahalers/Rotacaps-dry powder inhalation devices for asthma, presolar capsules - the first synergistic combination of a beta blocker and a sustained release calcium channel blocker for hypertension, Restyl tablets - the first anxiolytic-cum-anti depressant, Theo-Asthalin SR tablets - the first sustained release combination of two widely used bronchodilators, bromolin dry syrup and bromolin-250 capsules - antibiotic-cum-mucolytic agents, dilgard tablets - a new calcium channel blocker for angina, ibugesic plus suspension - a non steroidal anti inflammatory and anti-pyretic analgesic for paediatric use.

- 75,092 Bonus equity shares issued in proportion 1:1.


- The latest drugs introduced during the year were (i) Ciplox tablets (250 & 500 mg.) and infusion (50 and 100 ml.), a broad spectrum fluoroquinolone antibacterial for severe infections, (ii) cefadur capsules (250 & 500 mg.) and syrup (30 ml.), a cephalosporin antibiotic, (iii) Ulcimax tablets (20 & 40 mg.), a long-acting H2 antogonist for peptic ulcers and (iv) theoped syrup, a paediatric bronchodilator. Sales in the Company's `PROTEC' division exceeded Rs 5.50 crores for the second year of its operations.


- The Company launched several new products viz., Aerocort inhaler, an anti-inflammatory bronchodilator, Norflox eye/ear drops - a broad spectrum fluoroquinolone antibacterial, Pirox Gel - the first topical piroxicam formulation in the country, Cofenac tablets - an anti-infammatory analgesic, Kinetal 400 tablets - a multi-functional drug for vascular insufficiency, Novaclox Ped tablets - a dispensible combination antibiotics, Terfed tablets and Suspension - a new non-sedative antihistamine, Depryl tablets - a broad - spectrum antidepressant, Asthalin Respirator Solution - a bronchodilator for pressure ventilation in acute asthma. The Company spent Rs 4.22 crores on R&D and Rs 8.09 crores on modernisation and expansion of plant and machinery.


- The new products launched during the year were lomac capsules - a new antiulcerant, cromal inhaler - the first optimum - dose inhalant prophylactic for asthma, ciplox eye drops - the total bactericide for ocular infections, etosid injection - the first injection of indigenously manufactured etoposide for cancer therapy, proflox tablets - a key fluoroquinolone antibiotic and vasopril tablets - an ACE inhibitor for long-term management of hypertension. The research and development win g of the Company developed during the y ar felodipine - the latest anti-hypertensive drug, selegilinje - a new bulk drug for the treatment of Parkinson's disease, cetirizine HCI - an anti-histamine drug and nimodipine - a cerebral vasodilator. Work on the anti-AIDS drug AZT reached an advance stage of development. The research and development wing also developed anthelmintics oxfendazole and oribendazole, two veterinary products for exports.

- In May, 6,000 equity shares offered at par as rights to pref. shareholders in prop. 1:1. Only 5,216 shares taken up. Allotment of 5 equity shares pending.


- Some of the new products introduded were Zidovir capsules an antiretroviral for HIV injection, Cipril tablets for hypertension, Optipres eyedrops for glaucoma patients, Felogard for hypertension, Nodine, a non-narcotic analgesic, etc.

- In compliance with the provisions of the Companies Act, 1956, the Company redeemed its 6,000 preference shares of Rs 100 each as on 30th September.

- Pref. shares redeemed on 30.9.92, 1,55,395 bonus equity shares issued in prop. 1:1.


- New products introduced were - Beclate Aquanase - a major advancement in allergic rhinitis; Cytoplatin - an anticancer agent; Forcan - an antifungal; Imusporin - an immunosuppressant in organ transplantation; Kelfer - an iron chelator for thalassaemia; Lanzol - a proton pump inhibitor; Nuzac - an antidepresant; Odirox - a macrolide antibiotic and Qinarsol - for chloroquin-resistant malaria.

- Equity shares subdivided 155,39,500. Equity shares allotted shares issued in prop. 1:5.

- The Company's manufacturing unit at Kurkumbh, which was commissioned in April. The second phase of expansion of the location was under way and this was to provide specialised facilities for the manufacture of new chemical entites.


- Effective 4th July, the Company was forced to declare a lock-out as some of the workmen at the Vikhroli Unit resorted to indiscipline. The Company initiated steps to mitigate the impact it could have on production.

- New products introduced were - Acivir - antivirus herpes, Anlopres - antivirus herpes, Anlopres - Calcium channel blocker in hypertension and angina, Anlopres AT - a combination antihypertensive, Budecort 200 - a higher strength corticosterord in bronchial asthma, Budenase AQ - a corticosteroid protection in allergic rhinitis, cronal - a nast cell stabiliser in allerg ic conjunctivitis, cytonid - a antiandrogenic agent in prostate cancer, Norflox - an antidiarrhoeal in diarrhoea of mixed origin, optipes S - betaxocol eye drops, profenac - anti-inflammatory eye drops, Terfed D - a combination antihistamine and decongestant, Trivedon 20 - used in ischaemic heart disease.

- A new chemical entity, candocuronium iodide - a neuromuscular blocking agent was manufactured, other new bulk drugs manufactured include: Acyelovir - antiviral, Amlodipine besylate - antihypertensive and antianginal, Febantel - veterinary anthelmintic, Flutamide - antiandrogen, Flutivcasone dipropionate - a corticosteriod, zenprolide acetate - GMRH analogue.

- 13,43,383 rights equity shares issued (Prem. Rs. 60/-). However, the Rights issue was underwritten.


- The products launched during the year were Azee (azithromycin capsules) - a new macrolide antibiotic; Budecort (budesonide rotacaps) - dry powder inhaled corticosteriod therapy for asthama; Cipril H (lisionopril + hydrochlorothiazide tablets) - a combination antihypertensive; Ciplox TZ (ciprofloxacin + tinidazole tablets) - the combination bactericide for aerobic/anaerobic infections; Entosec (secnidazole tablets) - single dose therapy for amoebiasis/trichomoniasis; Fincar (fin asterid tablets) - for beign prostatic hyperphasia; Metolar (metaprolol injection) - beta-blocker protection for post myocardial infarction & Zoflut (fluticasone propionate cream) - a new topical corticosteroid.


- The products introduced during the year were; Alerid-D - an antihistamine and decongestant for cold and congestion, Amlopres L - a tablet for hypertension, Apuatears - an eye drop, Azee 1000 - a single dose for STDs, Budecort Respules - neubulised corticosteroid therapy for asthma, Dilgard XL - a diltiazem, Glumet - tablet for obese diabetics, Glygard - tablet for abese diabetics, Glygard - tablet for diabetics, Ipranase AQ (ipratropium nasal spray) - an anticholinergic therapy for rhinorrhoea, Ocutim (an eye drop) - a glaucoma therapy in acquafilm formulation, Osteifos 10 - tablet for osteoporosis, Prolyte Fizz - a rehydration effervescent tablet, Pylokit - an advanced H pylori kit, Risnia - an a typical antipsychotic, Stavir - an antiretroviral for AIDS, Synclar 250 - an advanced macrolide antibiotic, Theoday - a tablet for asthma, Zoflut Lotion - a topical corticosteroid.

- The bulk division of the Company had taken up, the development and manufacture of some new drugs viz., budesonide - antiasthmatic corticosteroid, carvedilol - alpha/beta blocker, ebastine - antihistamine, formoterol fumarate - antiasthmatic, meloxicam - for osteroarthritis and rheumatoid arthritis, moclobemide - antidepressant, mometasome furoate - antiflammatory corticosteroid, pantorazole sodium sesquihydrate - antiulcerant, sildenafil citrate - erectile dysfuncion.

- The Company has developed a form-fill-seal equipment for the first time in India, for the manufacture of sterile formulations. This was commissioned at Vikhroli factory and is working to its full capacity. Additional capacities were set up at Kurkumbh for manufacture of effervescent tablets, soft gel capsules and injectable formulations. The Company has incurred a capital expenditure of Rs 22.73 crores during the year.

- The Rs. 3.69 billion Cipla has finalised a marketing joint venture with Australia-based Genpharm, as part of its strategy to consolidate its global presence. - Pharmaceutical major Cipla Ltd grabbed the attention of traders at the Mumbai Stock Exchange (BSE) on December 26 after a large block of about 75,000 shares of the company valued at little over Rs 5 crore changed hands.

- The Rs.369-crore Cipla Ltd has entered into a souring arrangement with US-based Geneva Pharmaceuticals, a wholly-owned subsidiary of Swiss multinational Ciba, for a range of generic drugs.


- Pharmaceutical companies, Cipla and Wockhardt, will be seeking shareholders' approval for a proposed share buyback at their forthcoming annual general meetings.

- In a notice to shareholders, Cipla has proposed introduction of a new article, Article 64 A, in the Articles of Association of the company to enable the company to purchase and re-issue any of its shares. The existing Article 64 prohibits the company from buying its own shares and applying any of its funds for the purchase of any shares of the company.

- The share price of Cipla Ltd, the leading pharmaceutical company scaled a new peak of Rs 920 on the Mumbai Stock Exchange on Sept 29 following fresh bull charge. The scrip opened at Rs 900 and shot up to Rs 920 during mid-session and closed at Rs 884 following hectic trading activities.


- Ranbaxy and Cipla, have entered into a strategic partnership to jointly market a select basket of drugs. The alliance will bring forth their strengths in the strongly emerging cardiovascular and perennial anti-infectives market.

- As a first step, the two molecules being jointly launched are Carvedilol, a new generation anti-hypertensive and Cefpodoxime Proxetil, an advanced third generation oral cephalosporin.

- The Rs 541-crore Cipla has forged a strategic alliance with the UK-based Neolab for marketing a range of generic drugs. The alliance, while improving the Indian company's access to the multi-billion dollar European market for off-patent drugs, will also see Cipla rake in royalties on sales of products covered under the deal. - Cipla's latest tie-up in the international market comes close on the heels of the company's strategic partnership with the Delhi-based Ranbaxy Laboratories for a select basket of drugs. - The Mumbai-based Cipla is working on abbreviated new drug applications (ANDAs) in collaboration with international generics firms for a range of products like flutamide (for advanced prostatic cancer) and felodipine, for hypertension.


- Cipla and Ranbaxy Laboratories have expanded an existing partnership by adding one more new drug in their co-marketing arrangement.


- Cipla has tied up with the US-based Zenith Goldline and United Research Labs for marketing Flutamide, an oncology drug, and Felodipine, a cardiovascular drug, in the US and European markets.

- Domestic pharma giant, Cipla, has despatched its first free consignment of anti-AIDS drug, `Nevirapine', to the Indian Government for distribution under the public health system. 2002

-Reduces the price of its anti-HIV medicines such as Stavir, Lamivir, Nevimune, Dinex, Indivan, Triomune, Efavir and Duovir

-Revokes interim dividend of Rs 5 per share on face value of Rs 10 per share for FY 2001-02

-Company included in the World Health Organisation's (WHO's) list of HIV-related products

-Chairman and Managing Director YK Hamied was presented with the lifetime contribution award for excellence in the pharmaceutical industry by Union chemicals & fertilisers minister SS Dhindsa

-Resigns from Indian Pharmaceutical Alliance (IPA) over Patents Bill


-Applies its requisiton for Abbreviated New Drug Application (ANDA) with US regulators for a post-menopausal drug

-National Pharmaceutical Pricing Authority (NPPA) issues notices to Cipla along with Ranbaxy for overcharging the products

-Completes research studies on three Anti-HIV Drugs

-Registers Stavudine, Nevirapine, other anti-AIDS products in South Africa


-Signs long-term agreement with Morton Grove Pharmaceuticals Inc (MGP) of Illinois, US, for product launch in the US market

-Avesthagen forges alliance with Cipla

-Cipla has joined a global initiative taken up by the Vatican in collaboration with global generic pharmaceutical manufacturers and the International Federation of Catholic Pharmacies and Academics to float CUMVIVIUM

-Cipla join hands with Pentech Pharma

-Indian pharma major Cipla, a pioneer in supplying cheap generic AIDS drugs in Africa, has patented its three-in-one combination tablet Triomune in South Africa

-Cipla introduces 'Duova' to fight chronic obstructive pulmonary disease

- Launches a new treatment for arthritis in technical collaboration with California-based Cymbiotics Inc.

2005 -Set-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh. -Cipla introduces new drug for arthritis

-Cipla to sign deal with Akorn Inc for anti-infective drug

-Cipla to produce generic versin of bird-flu drug

-Cipla to join hands with Roche

- Cipla introduces new drug for arthritis


- Cipla receives Scrip Award for Best Company in an Emerging Market

-Safe & steady strategy gives Cipla lead over Ranbaxy

-Cipla sets up subsidiary in Dubai

-Cipla ties up with Ivax for US market

-Cipla receives tentative US FDA approval for AIDS drugs

-Cipla receives Pharma Excellence Award for 'Sustained Growth'

-Cipla has given the Bonus in the Ratio of 3:2


- Cipla unveils anti-malaria global initiative.

-Set-up state-of-the-art facility for manufacture of formulations at Sikkim.

-Award for the Forbes Asia's Best Under A Billion List!

-Cipla's drug included in US anti-AIDS initiative

-Anti-AIDS blitz sees pharma firms locked in ugly battle

-Cipla launches emergency contraception tablet

-Cipla launches estradiol transdermal spray in India

-Cipla launches cut-price zanamivir in India

-Cipla receives International Trade Awards 2006 for outstanding exporter of the year (Pharmaceuticals, Healthcare and Life Sciences category)


-Cipla Ltd has appointed Mr. Pankaj Patel as a Director in casual vacancy with effect from March 05, 2008.

-Cipla launched Roche's generic version of anti-infection drug


-Cipla wins Erlotinib case against Roche

-Pharmaceuticals Export Promotion Council Awards

-Cipla launches drug to treat Swine flu virus

-Cipla wins patent fight against Gilead Sciences


-Cipla Ltd acquired Meditab Specialities Pvt. Ltd. ("Meditab") for an aggregate consideration of Rs. 133.35 crores.

-Cipla Medpro has signed a deal with Biomab, a division of Chinese company Desano Pharma.

-Cipla sold the marketing rights of i-Pill to Piramal Healthcare for Rs 95 crore in cash.

-Cipla has tied up with the Manipal Group-promoted 'Stempeutics Research'.

- Drug Maker Cipla has launched the generic Version of Pirfenidone, used to treat Idiopathic Pulmonary Fibrosis, a progressive Lung disease.India is the 2nd market to have this drug after Japan.


-Cipla Cancer Palliative Care Centre launched 24 hour helpline to offer counselling to ensure more people use of the free services available.


-Cipla India's second largest drug firm, has agreed to acquire South African Drugmaker Cipla Medpro with 51% stake amounts to $220 Million.

-Cipla bags tentative approval for HIV treatment tablets

-Drug giant Cipla Ltd has announced price reduction on 3 major anti-cancer drugs including Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD).

-Cipla bags award in the Field of Export of Pharmaceuticals during the year conferred the Highest Award 'Platinum'.

2013 -Cipla announces an offer to the shareholders of Medpro for 100% acquisition -Cipla launches the first Biosimilar of Etanercept in India

2014 -Cipla wins USD 188.95 million of Global Fund ARV Tender -MMV announces collaborations with Cipla and Strides -Cipla licenses rights for innovative product - Cipla, S&D Pharma collaborate to enter Czech Republic and Slovakia -Cipla collaborates with Hetero to launch its second biosimilar drug `Darbepoetin alfa' -Cipla invests in Chase Pharmaceuticals to support Alzheimer's disease drug development -The Registered Office of the Company has been shifted from Mumbai Central, Mumbai - 400008 to Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013, Tel: 022-24826000 / 022-2482695,1Fax: 022-24826893.

2015 -Cipla Ltd has entered into an agreement with partner, Biopharm SPA, to form a joint venture (JV) company in Algeria. -Cipla Ltd has launched the generic drug Sofosbuvir in brand name Hepcvir -Cipla Ltd has inked an agreement with Serum Institute of India Ltd. (SII) to market flu vaccine Nasovac-S. -Cipla Ltd has entered into a definitive agreement with Biopharma SPA for establishing a joint venture company in Algeria. -Cipla Ltd has launched a anti-ageing skin care product Cutisera&trade. developed by Stempeutics. -Cipla has launched generic tablets used for treating of hepatitis C under the brand name Hepcvir-L

2016 -Cipla gets CCI approval for investment by FIL Capital -Cipla completes acquisition of generic businesses in US -Cipla gets USFDA nod for generic anti-depressant drug -Cipla gets EIR from US FDA for Indore facility -Cipla gets USFDA final nod for Hepatitis B treatment drug -Cipla receives final approval for generic Baracluder tablets

2017 - Cipla Ltd "Authorised Key Managerial Personnel to determine materiality of events/information". - Cipla launches Hepatitis B vaccine in India - Cipla receives approval for Lamivudine Tablets - Cipla USA signs licensing agreement with MEDRx - Cipla gets WHO nod to sell TB preventing drug in HIV patients - Cipla launches Q-TIB globally - Cipla launches Rectal Artesunate Suppositories for severe malaria in young children - Cipla Receives Final Approval for Generic Epzicomr Tablets - Cipla launches Hepatitis B vaccine in India

2018 -Cipla teams up with Roche Pharma to sell cancer therapy drugs in India. -Cipla partners with Eli Lilly to market diabetes drug Basaglar in India. -Cipla receives final approval for generic version of Valganciclovir Tablets 450mg from the United States Food and Drug Administration (USFDA). -Cipla bags DMA Asia Echo Award (Silver) for Best Digital Destination and Leader Certificate in Pharma & Healthcare category.

2019 -Cipla to launch cinacalcet hydrochloride tablets in US market. -Cipla introduces Niveoli, India's first HFA inhaler for airway diseases. -Cipla receives the 18th ICSI (Institute of Company Secretaries of India) National Award for Excellence in Corporate Governance in January 2019.

2020 -Cipla completes successful phase-3 clinical study of generic asthma drug. -Cipla inks licensing pact with Gilead Sciences for potential COVID-19 treatment drug. -Cipla launches generic remdesivir for coronavirus patients. -Cipla, Stempeutics collaborate to launch Stempeucel for CLI treatment in India. -Cipla launches antibody detection kit for COVID-19 in India. -Cipla has been conferred with the 'Golden Peacock Global Award for Excellence in Coporate Governance for the year 2020.

2021 -Cipla sets up 30 MW solar plant in Maharashtra. -Cipla partners with Alvotech to market biosimilars medicines in Australia and New Zealand. -Cipla bags the National Energy Conservation Award 2021 in drug & pharmaceutical sector by the Bureau of Energy Efficiency, Ministry of Power, Government of India. -Cipla wins Gold for Remdesivir in 'Covid Care Brand' Category.

2022 -Cipla announces launch of leuprolide acetate injection depot (22.5mg). -Cipla receives USFDA approval for generic version of Revlimidr (Lenalidomide Capsules). -Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa. -Cipla scored highest among pharma companies in CRISIL's Sustainability Rating 2022. -Cipla wins the prestigious Frost & Sullivan and TERI's Sustainability 4.0 Award.

2023 -"Acquisition of additional stake in GoApptiv Private Limited". -Cipla to acquire South Africa-based Actor Pharma.